150 related articles for article (PubMed ID: 37062213)
21. Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma.
Rios-Doria E; Momeni-Boroujeni A; Friedman CF; Selenica P; Zhou Q; Wu M; Marra A; Leitao MM; Iasonos A; Alektiar KM; Sonoda Y; Makker V; Jewell E; Liu Y; Chi D; Zamarin D; Abu-Rustum NR; Aghajanian C; Mueller JJ; Ellenson LH; Weigelt B
Gynecol Oncol; 2023 Jul; 174():262-272. PubMed ID: 37245486
[TBL] [Abstract][Full Text] [Related]
22. Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment.
Leon-Castillo A; Horeweg N; Peters EEM; Rutten T; Ter Haar N; Smit VTHBM; Kroon CD; Boennelycke M; Hogdall E; Hogdall C; Nout RRA; Creutzberg CL; Ortoft G; Bosse T
Gynecol Oncol; 2022 Mar; 164(3):577-586. PubMed ID: 35078648
[TBL] [Abstract][Full Text] [Related]
23. Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer.
Imboden S; Nastic D; Ghaderi M; Rydberg F; Siegenthaler F; Mueller MD; Rau TT; Epstein E; Carlson JW
Gynecol Oncol; 2021 Aug; 162(2):394-400. PubMed ID: 34127276
[TBL] [Abstract][Full Text] [Related]
24. Analysis of the immune checkpoint lymphocyte activation gene-3 (LAG-3) in endometrial cancer: An emerging target for immunotherapy.
Zhang Y; Yang R; Xu C; Zhang Y; Deng M; Wu D; Tang F; Liu X; Han Y; Zhan Y; Miao J
Pathol Res Pract; 2022 Aug; 236():153990. PubMed ID: 35749914
[TBL] [Abstract][Full Text] [Related]
25. Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study.
Kim SR; Tone A; Kim RH; Cesari M; Clarke BA; Eiriksson L; Hart T; Aronson M; Holter S; Lytwyn A; Lajkosz K; Oldfield L; Gallinger S; Bernardini MQ; Oza AM; Djordjevic B; Lerner-Ellis J; Van de Laar E; Vicus D; Pugh T; Pollett A; Ferguson SE
Gynecol Oncol; 2021 Apr; 161(1):221-227. PubMed ID: 33478752
[TBL] [Abstract][Full Text] [Related]
26. Classification of high-grade endometrium carcinomas using molecular and immunohistochemical methods.
Bayramoglu D; Seçilmiş Kerimoğlu Ö; Bayramoğlu Z; Çintesun E; Şahin G; Karabağlı P; Çelik Ç
Ginekol Pol; 2023; 94(1):3-11. PubMed ID: 35072228
[TBL] [Abstract][Full Text] [Related]
27. Selection of endometrial carcinomas for p53 immunohistochemistry based on nuclear features.
Kang EY; Wiebe NJ; Aubrey C; Lee CH; Anglesio MS; Tilley D; Ghatage P; Nelson GS; Lee S; Köbel M
J Pathol Clin Res; 2022 Jan; 8(1):19-32. PubMed ID: 34596362
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathologic significance of DNA mismatch repair protein status in endometrial cancer.
Kim JH; Kwon BS; Kim H; Suh DH; Kim K; Kim YB; No JH
Taiwan J Obstet Gynecol; 2022 May; 61(3):415-421. PubMed ID: 35595431
[TBL] [Abstract][Full Text] [Related]
29. Incorporation of molecular characteristics into endometrial cancer management.
Vermij L; Smit V; Nout R; Bosse T
Histopathology; 2020 Jan; 76(1):52-63. PubMed ID: 31846532
[TBL] [Abstract][Full Text] [Related]
30. Impact of oestrogen and progesterone receptor expression in the cancer cells and myometrium on survival of patients with endometrial cancer.
Tomica D; Ramić S; Danolić D; Šušnjar L; Perić-Balja M; Puljiz M
J Obstet Gynaecol; 2018 Jan; 38(1):96-102. PubMed ID: 28764605
[TBL] [Abstract][Full Text] [Related]
31. Preoperative MR imaging for ESMO-ESGO-ESTRO classification of endometrial cancer.
Lavaud P; Fedida B; Canlorbe G; Bendifallah S; Darai E; Thomassin-Naggara I
Diagn Interv Imaging; 2018 Jun; 99(6):387-396. PubMed ID: 29472031
[TBL] [Abstract][Full Text] [Related]
32. Mismatch repair deficiency and aberrations in the Notch and Hedgehog pathways are of prognostic value in patients with endometrial cancer.
Polychronidou G; Kotoula V; Manousou K; Kostopoulos I; Karayannopoulou G; Vrettou E; Bobos M; Raptou G; Efstratiou I; Dionysopoulos D; Chatzopoulos K; Lakis S; Chrisafi S; Tsolakidis D; Papanikolaou A; Dombros N; Fountzilas G
PLoS One; 2018; 13(12):e0208221. PubMed ID: 30521558
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.
Cosgrove CM; Cohn DE; Hampel H; Frankel WL; Jones D; McElroy JP; Suarez AA; Zhao W; Chen W; Salani R; Copeland LJ; O'Malley DM; Fowler JM; Yilmaz A; Chassen AS; Pearlman R; Goodfellow PJ; Backes FJ
Gynecol Oncol; 2017 Sep; 146(3):588-595. PubMed ID: 28709704
[TBL] [Abstract][Full Text] [Related]
34. A novel algorithm to implement the molecular classification according to the new ESGO/ESTRO/ESP 2020 guidelines for endometrial cancer.
Betella I; Fumagalli C; Rafaniello Raviele P; Schivardi G; De Vitis LA; Achilarre MT; Aloisi A; Garbi A; Maruccio M; Zanagnolo V; Aletti G; Guerini-Rocco E; Mariani A; Maggioni A; Barberis M; Colombo N; Multinu F
Int J Gynecol Cancer; 2022 Jun; ():. PubMed ID: 35732351
[TBL] [Abstract][Full Text] [Related]
35. p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial.
Vermij L; Léon-Castillo A; Singh N; Powell ME; Edmondson RJ; Genestie C; Khaw P; Pyman J; McLachlin CM; Ghatage P; de Boer SM; Nijman HW; Smit VTHBM; Crosbie EJ; Leary A; Creutzberg CL; Horeweg N; Bosse T;
Mod Pathol; 2022 Oct; 35(10):1475-1483. PubMed ID: 35752743
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy.
Li JY; Park HS; Huang GS; Young MR; Ratner E; Santin A; Damast S
Gynecol Oncol; 2021 Dec; 163(3):557-562. PubMed ID: 34602287
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification.
Karnezis AN; Leung S; Magrill J; McConechy MK; Yang W; Chow C; Kobel M; Lee CH; Huntsman DG; Talhouk A; Kommoss F; Gilks CB; McAlpine JN
J Pathol Clin Res; 2017 Oct; 3(4):279-293. PubMed ID: 29085668
[TBL] [Abstract][Full Text] [Related]
38. Targeted Molecular Testing in Endometrial Carcinoma: Validation of a Clinically Driven Selective ProMisE Testing Protocol.
Talhouk A; Jamieson A; Crosbie EJ; Taylor A; Chiu D; Leung S; Grube M; Kommoss S; Gilks CB; McAlpine JN; Singh N
Int J Gynecol Pathol; 2023 Jul; 42(4):353-363. PubMed ID: 36731023
[TBL] [Abstract][Full Text] [Related]
39. Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer.
Chung YS; Woo HY; Lee JY; Park E; Nam EJ; Kim S; Kim SW; Kim YT
Am J Obstet Gynecol; 2021 Apr; 224(4):370.e1-370.e13. PubMed ID: 33039397
[TBL] [Abstract][Full Text] [Related]
40. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer.
Ramchander NC; Ryan NAJ; Walker TDJ; Harries L; Bolton J; Bosse T; Evans DG; Crosbie EJ
Front Immunol; 2019; 10():3023. PubMed ID: 31998307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
